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Abstract 
 
Purpose: 
Hyperbaric oxygen (HBO) has been advocated in the prevention and treatment of 
osteoradionecrosis of the jaws following head and neck radiotherapy, but supporting 
evidence is weak. The aim of this randomized trial was to establish the benefit of HBO in 
prevention of osteoradionecrosis following high risk surgical procedures to the irradiated 
mandible. 
 
Methods and Materials: 
XXXXXX was a randomized controlled phase 3 trial.  Participants were recruited who 
required dental extractions or implant placement in the mandible with prior radiotherapy 
>50Gy.  Eligible patients were randomly assigned (1:1) to receive, or not receive HBO. All 
patients received chlorhexidine mouthwash and antibiotics. For patients in the HBO arm, 
oxygen was administered in 30 daily dives at 100% oxygen to a pressure of 2.4 ATA for 80-90 
minutes.  The primary outcome measure was the diagnosis of osteoradionecrosis six months 
following surgery as determined by a blinded central review of clinical photographs and 
radiographs.  Secondary endpoints included grade of osteoradionecrosis, osteoradionecrosis 
at other time-points, acute symptoms, pain and quality of life.  
 
Results: 
144 patients were randomised, and 100 were analysed for the primary endpoint.  The 
incidence of osteoradionecrosis at 6 months was 6.4% and 5.7% for the HBO and control 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 2
groups respectively, OR 1.13, P = 1 (95% CI: 0.14 to 8.92). Patients in the hyperbaric arm had 
fewer acute symptoms but no significant differences in late pain or quality of life. Drop-out 
was higher in the HBO arm, but baseline characteristics of groups completing the trial were 
comparable between the two arms.  
 
Conclusions: 
The low incidence of osteoradionecrosis seen makes it unnecessary to recommend HBO for 
dental extractions or implant placement in the irradiated mandible.  These findings are in 
contrast to a recently published Cochrane review and previous trials reporting rates of ORN 
(non-HBO) of 14-30%, and challenge a long-established standard of care.  
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Introduction 
 
Osteoradionecrosis (ORN) is exposed necrotic bone following radiotherapy in the absence of 
cancer recurrence(1,2). Mandibular ORN is a common complication of head and neck 
radiotherapy causing pain, infection and malnutrition. The incidence of head and neck 
malignancy and use of radiotherapy is rising(3), as is survival(4), thus the at-risk population 
for ORN is increasing. 
 
The risk of ORN is higher in the posterior mandible and if more than 60 Gray has been 
received(5,6).  In order to prevent ORN, dental health is optimized prior to radiotherapy(7), 
however dental surgery such as extractions or implant placement is often indicated.  The 
risk of such procedures in precipitating ORN is unknown but has been reported as 20-
30%(6,8).  The overall cumulative incidence of spontaneous ORN may have reduced with the 
adoption of intensity modulated radiotherapy(9,10), but the specific risk to patients caused 
by dental procedures is less clear. 
 
The role of hyperbaric oxygen (HBO) in the prevention of mandibular ORN following dental 
procedures remains controversial(11,12). Marx’s randomized controlled trial(8) showed a 
lower incidence of ORN after dental extractions with HBO (5.4%) than when treated with 
penicillin (29.9%) . Vudiniabola et al(13) 
 
showed that of 29 patients who received HBO, one 
(3.4%) developed ORN; and of 7 patients who did not receive HBO, one (14.3%) developed 
ORN. Prophylactic HBO became a standard of care for high risk dental extractions(14) on the 
basis of this limited evidence. Other trials have not demonstrated benefit for HBO in the 
treatment of established mandibular ORN(15), or in late radiation toxicities to other 
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anatomical sites(16).  Similarly, controversy surrounds the role of HBO in the placement of 
implants in the irradiated mandible, where there is conflicting evidence(17,18) from 
retrospective series.  The costs and logistic arrangements implicit in 30 daily treatments 
with HBO present a barrier to universal adoption.  In a recent Cochrane review(19), it was 
concluded that HBO reduced the chance of ORN following a tooth extraction, but stressed 
the need for further well designed studies. 
 
In order to address the paucity of evidence, we conducted the XXXXXX trial.  The aim of this 
randomized trial was to establish the benefit of HBO in prevention of ORN following high-
risk surgical procedures to the irradiated mandible. Additionally, the XXXXXX trial aimed to 
define the changes in acute symptoms accompanying surgery, long-term pain and quality of 
life resulting from use of HBO, as well as to determine the risk of ORN. 
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Methods 
 
The XXXXXX trial was a randomized controlled phase III study.  The patients and site 
investigators were unblinded, but assessment of the primary endpoint was blinded, as it 
was remotely assessed by a blinded expert panel of investigators. The trial was conducted in 
16 acute UK hospitals, one acute hospital in Denmark, and nine UK hyperbaric medicine 
facilities registered with the British Hyperbaric Association. The XXXXXX trial protocol was 
granted ethical approval by Greater Manchester Central Research Ethics Committee (REC 
reference 08/H1008/32).  The study protocol is available at XXXXXXX and a more detailed 
description has been published(20).  The phase III analysis incorporates data from the 
preceding XXXXXX phase II feasibility study with parallel trial inclusion, randomisation, 
procedures and assessments for the first 48 randomised patients. 
 
Participants 
Eligible participants were men and women aged 18 years or older with an indication for 
surgery to the mandible and prior radiotherapy to the mandible of at least 50Gy. Indications 
for surgery included extraction of premolar or molar teeth or the placement of 
osseointegrated dental implants.  
 
Randomisation  
Eligible patients were randomly assigned (1:1) to receive, or not receive HBO. Allocation of 
treatment was unblinded to site investigators and patients.  
 
Procedures 
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Patients in both arms of the trial were given chlorhexidine mouthwash and antibiotics. Pre- 
and post-operative chlorhexidine mouthwash 0.2% was used in a volume of 10ml rinsed 
around the mouth for around 1 minute and spat out, three times daily for 5 days post-
operatively. Orally administered antibiotics comprised amoxicillin 3g one hour pre-
operatively, or 1g administered intravenously, and 250mg three times daily for 5 days post-
operatively. Suitable alternatives were used to substitute for chlorohexidine or amoxicillin in 
the case of allergy. For patients in the HBO arm, oxygen was administered at 2.4 ATA for 80-
90minutes, in 30 daily treatments, 20 immediately prior to and 10 after surgery. The trial 
procedures are summarised in figure 1.  For those patients who developed ORN, their 
subsequent management was not specified in the trial protocol, however the grade of ORN 
was followed to the 12 month timepoint. 
 
Outcomes 
The primary outcome measure was the presence or absence of osteoradionecrosis (ORN) six 
months following surgery, determined by a blinded central review of clinical photographs 
and radiographs and classified using the modified Notani score(1,20,21) (supplementary 
table 1). The secondary endpoints were: ORN similarly assessed at three and twelve 
months; pain; and quality of life.  Additionally, acute symptoms (pain, swelling, trismus and 
diet) were self-recorded during the first week following surgery.  
 
Sample Size - Stopping Rules 
The incidence of ORN in the control arm was anticipated to be 18-19%, as evidenced by 
prior trials such as those of Marx et. al.(8) and Vudiniabola et. al.(13) who reported 
comparable rates of 30% and 14% respectively. Based on this, 103 evaluable patients per 
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group would provide 80% power to detect an odds ratio of 0.23, equating to a rate of 18.5% 
in the control arm and 5% in the HBO treatment arm, with a difference of 13.5%. Estimating 
the dropout rate at 7%, planned recruitment was 221 patients. A single interim analysis was 
planned when 100 patients had been followed up for 6 months, using the Peto stopping rule 
for the primary efficacy outcome. 
 
Statistical Analysis 
For the patients in the HBO arm, the additional treatment prior to surgery risked higher 
drop out than in the standard arm. The full analysis set used for the primary analyses was 
therefore defined as all randomised patients who had received surgery according to the 
treatment group originally allocated.  The validity of this approach was supported by a range 
of sensitivity analyses. The primary test of efficacy was performed using a Fisher’s exact test 
with exact logistic regression used to obtain exact 95% confidence intervals about an odds 
ratio. The null hypothesis was that HBO treatment was not more effective than standard 
care, i.e. the odds ratio was not statistically different from 1, while the alternate hypothesis 
was that HBO treatment was superior with an odds ratio of 0.23 or less. A two-sided test, 
with P-value of less than 0.05 was declared statistically significant. Significance tests for 
secondary endpoints were two-sided at 5% accompanied by 95% two-sided confidence 
intervals.  
 
An Independent Safety Data Monitoring Committee oversaw the XXXXXX trial.  
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Results 
 
144 patients were randomized between 2008 and 2016, 72 (50%) into the HBO arm and 72 
(50%) into the non-HBO arm. Drop-out after randomization, but prior to treatment, was 
higher in the HBO arm, with 17/72 (24%), compared with 6/72 (8%) in the non-HBO arm.  19 
(13%) patients withdrew from study between surgery and the primary endpoint, 7/72 (10%) 
in the HBO arm and 12/72 (17%) on the non-HBO arm.  One patient in each arm was 
determined to be ineligible on review and there was a total of 100 patients available for the 
primary analysis with 47 in the HBO arm and 53 in the non-HBO arm (Figure 2).  A further 
seven patients, four on HBO and three on non-HBO withdrew from the study after providing 
data on the primary outcome.  Despite the differences in drop-out rate, the baseline 
characteristics were similar whether the comparison was made on those randomized, per 
protocol, or those analyzed for the primary endpoint (Table 1).  
 
The overall incidence of ORN at the primary endpoint was 6/100 (6%), 3/47 (6.4%) in the 
HBO arm and 3/53 (5.7%) in the non-HBO arm. The odds ratio for ORN was 1.13, two-sided 
Fishers Exact P>0.99 (95% CI: 0.14 to 8.92). For patients undergoing dental extractions, the 
odds ratio was 0.72, two-sided Fishers Exact P>0.99 (95% CI: 0.06 to 6.66).  The unblinded 
site investigators’ assessment of ORN at 6 months also showed no difference; odds ratio = 
1.02, two-sided Fishers Exact P>0.99(95% CI: 0.31 to 3.27). The IDMC recommended closing 
the trial after 100 evaluable patients as the rate of ORN seen was much less than that 
assumed, precluding statistically significant efficacy analyses for HBO. 
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The incidence of ORN at 3 months was 7%, 3/45 (7%) on the HBO arm and 4/55 (7%) on the 
non-HBO arm [OR 0.91 (two sided Fishers exact P>0.99 CI 0.13 to 5.72)]. None of the 
patients with ORN at 6-month primary endpoint had healed by 12 months, with the 
exception that one was lost to follow-up between these timepoints. No new ORN developed 
between 6 and 12 months. The grade of ORN at 6 months was Notani grade 1: 2 patients, 
Notani grade 2: 1 patient, Notani grade 3: 3 patients.  Of the 100 patients available for 
analysis, 16 (16%) had no dental extraction with a single case of ORN (6%) , 17 patients had 
a single extraction during surgery and two of these patents had ORN (11%) and 67 (67%) 
had multiple extractions with 3 (4%) of these patients experiencing ORN.  The difference in 
ORN between extraction status was not statistically significant (p=0.558). 
 
 
The incidence of minor bone spicules (MBS) at the primary endpoint was 13% ,  5/47 (10%) 
in the HBO arm and 8/53 (15%) in the non-HBO arm [odds ratio = 0.67, two-sided Fishers 
Exact P=0.5642 (95% CI:0.16 to 2.55)]. MBS was managed entirely conservatively without 
sequestrectomy, and as all cases with MBS in the primary analysis had fully healed by 12 
months, it is concluded this was by natural exfoliation. 
 
Analysis of the acute symptoms questionnaire showed that, for area under the curve, 
patients had less severe symptoms in the first 7 days after surgery in the HBO arm for pain 
(P=0.0458), swelling (P=0.0182), bleeding (P=0.0375), mouth opening (P=0.004) and eating 
(P=0.004) (Table 2). The patients were unblinded to allocation, and these results reflect 
analysis of those 75% returning questionnaires (39 patients in the HBO arm, 36 patients in 
the non-HBO arm). A higher proportion (65%) of HBO arm patients were comfortable at day 
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8 post-surgery than in the non-HBO arm (35%) Exact OR 2.79, two sided-Fishers Exact 
P=0.038 (95% C.I. 1.01 to 8.05).  
 
Patients’ experience of pain as assessed by visual analogue scores collected at baseline, 3,6 
and 12 months are summarized in Table 3.  Pain was lower in the HBO arm than non-HBO 
arm at all timepoints. However, the differences were small and of borderline statistical 
significance, and the absolute levels of pain were very low at 3,6 and 12 months.  Pain 
scores reduced by 0.044 units per month in the non-HBO arm and 0.076 units in the HBO 
arm.  These very small differences, i.e. less than 0.1 in the context of a 0-10 scale, are of 
doubtful clinical significance (Supplemental Table 2). 
 
 
The measures of Quality of Life (QoL) in each arm were similar, with a marginal advantage 
for the HBO arm being partly attributable to a slight advantage at baseline. QOL data is 
presented as a summary of trend for composite physical score (Figure 3) and composite 
social score (Figure 4) for UW-QoL data obtained at baseline, 3-, 6- and 12-months. The 
changes in UW-QoL seen over the trial timepoints were modest and did not differ 
significantly between HBO and non-HBO arm.  
 
Pain scores were very low, both for patients with full healing and for those with MBS;  
MBS: 0.1 (SD 0.22, 11 patients) versus Healed: 0.1 (SD 0.23, 81 patients). In contrast, mean 
pain was higher, at 0.3 (SD 0.3, 6 patients), for those patients with Notani grade 1,2 or 3 
ORN. This data shows that the symptoms of those with MBS were more similar to healed 
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patients than those with ORN. The categorization of MBS with other healed patients 
appears to be justified. 
 
For patients receiving dental implants, the loss of any implants was recorded beyond 12 
months to date of trial closure. Implant survival post-surgery was high, 95% at 24 months 
(95% CI: 74% to 99%) and 83% at 48 months (95% CI: 48% to 95%). There were 13 implant 
failures amongst 4 patients, with 4 implants being lost in 1 patient in the HBO arm, and 9 
implants in 3 patients in the non-HBO arm. The Hazard Ratio for implant loss in HBO versus 
non-HBO arms was 1.39; 95% CI 0.16 to 12.09, p= 0.765 (adjusted for clustering by patient).  
 
Safety within the trial was good, and adverse events related to HBO tended to be of low 
grade. There were no significant differences in death, hospital admission, incapacitation or 
further surgery between the arms. Adverse events potentially attributable to HBO are 
shown in supplemental table 3. Serious adverse events were mostly related to subsequent 
malignancies, occurring in 13% of patients within 12 months. Recurrence of head and neck 
malignancy occurred in 4%, at a new site in 6%, and uncertain origin in 3%. There were no 
significant differences in the incidence of malignancy between the arms, with 7 diagnoses in 
47 patients (15%) in HBO arm versus 6 in 53 patients (11%) in the non-HBO arm.  
 
A range of sensitivity analyses was performed to explore any potential effect of drop-out on 
the primary endpoint (Supplemental Table 4). None provided any conclusive support for 
either benefit or harm and show the overall results of the study to be robust under a variety 
of assumptions.   
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Discussion 
 
The incidence of ORN in the XXXXXX trial was 6%, therefore the risk to irradiated patients 
needing dental procedures is too low to routinely justify the use of HBO, and also likely 
precluding future prevention trials in this setting. This finding is in itself highly significant, 
contradicting the findings of a recent Cochrane review(19).  These results are in contrast 
with prior randomized trial evidence(8), but the overall incidence of ORN seen in the 
XXXXXX trial is consistent with a progressively declining trend reported in retrospective case 
series(22), cited as 7% in one recent study(9).  Alternative methods for prophylaxis of ORN 
include the use of pentoxyphlline and tocopherol. The single retrospective series(23) so far 
published confirms a very low rate of ORN, but reinforces the statistical challenges of 
powering randomized trials. 
 
The low rate of ORN seen in the present data raises the question of whether subsequent 
surgery in the irradiated mandible, such as extraction or implant placement, actually causes 
additional cases of ORN, or merely changes the timing of presentation for cases that would 
have developed spontaneously. The XXXXXX trial clarifies the incidence and natural 
progression of ORN in a tightly controlled prospective study, adding significant data to a 
field dominated by anecdote and retrospective case series. 
 
The reasons for the apparent reduction in risk of mandibular ORN may be attributable to 
more stringent dental protocols or more advanced, better targeted, radiotherapy 
techniques, such as intensity modulated radiotherapy (IMRT)(9,24).  IMRT can effectively 
allow salivary glands to be spared with improvements in xerostomia(10), and it may also be 
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that it has reduced the impact of radiotherapy to the mandible in head and neck 
malignancy. 
 
Regarding the secondary endpoints, there were significantly improved acute symptoms in 
the week following surgery in patients receiving HBO.  There was slight less pain reported by 
patients in the HBO arm at three, six and twelve months, but these differences were too  
small to be of any clinical relevance. There were only minor and insignificant differences in 
QOL associated with the use of HBO. Taken as a whole, these symptomatic effects appear to 
be temporally related to the HBO sessions, reducing over time. These outcomes reflect 
unblinded analyses, so the differences may reflect placebo effect or a biological mechanism 
of HBO, which may reflect an anti-inflammatory or anti-infectious effect. It has been 
demonstrated that late radiation injury is usually accompanied by vascular atrophy, and 
lacks steep oxygen gradients required for angiogenesis in surgical wounds(25).  This has 
been reversed in-vivo using 30 treatments of HBO and it is possible that such mechanisms 
might be able to improve symptoms in a dental extraction or implant wounds.  In a 
comparable trial of HBO in late radiation tissue injury of the pelvis, the HORTIS trial(26) , 
showed early significant symptomatic benefits associated with HBO, but the subsequent 
HOT2 trial(16) showed no benefit at one year.  
 
The strengths of the XXXXXX trial are mainly in the robust blinded nature of the primary 
endpoint assessment, and in the comparability between the two trial arms. The choice of 6 
months as the primary endpoint appears justified, as ORN when seen at this time was 
stable. None of the patients with ORN at 6 months had healed by 12 months, and no new 
cases developed between 6 and 12 months.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15
 
The use of the category minor bone spicules (MBS) aided the primary analysis, and its 
distinction from ORN, is of critical importance.  13% of patients developed MBS at the 
primary endpoint which was more than double the incidence of ORN at 6%.  The differences 
between MBS and ORN are clear in terms of severity, extent, symptoms and progression 
(Figures 5 and 6). All cases of MBS at the 6-month primary endpoint had spontaneously 
healed without intervention by 12 months whereas all cases of ORN at the primary endpoint 
persisted to 12 months.  MBS was essentially asymptomatic, with comparable pain scores to 
those patients who had fully healed, whereas patients with ORN had more pain. The 
disparity in clinical appearance of ORN versus MBS is illustrated in Figures XXXX. MBS 
should, therefore, be regarded as clinically innocuous and reflects delayed healing rather 
than progressive bone necrosis. It is concerning that this entity has not been clearly 
characterized and accounted for in the data of previous trials and series in the field(1). 
 
The current trial does not address the use of HBO in the management of established ORN, 
with or without surgical resection. Although this has been long-established, a previous 
prospective clinical trials did not find any benefit(15). A further trial led in Denmark by the 
DAHANCA group is underway exploring the role of HBO with surgical resection of ORN. 
 
Several difficulties were encountered during the XXXXXX trial, particularly that of slow 
recruitment. In previous work within the portfolio of head and neck cancer trials(27), we 
had identified that where two arms of the trial appear very different in nature, many 
patients would be more likely express a preference for one or other arm. Similarly, as HBO 
has been a long-established standard of care in this setting, it may be that not all recruiting 
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clinicians were able to effectively convey equipoise(28).   The unblinded nature of the data 
for assessment of acute symptoms, late pain and QOL means less weight can be attached to 
these secondary endpoints than the primary endpoint.  In this regard the use of sham HBO 
as a ‘placebo’ arm, although not without inherent problems, would have aided the unbiased 
assessments of these more subjective endpoints.    
 
An additional methodological concern was the high drop-out rate and disparity in drop-out 
rates between trial arms.  The dropout rate was particularly high early in the trial and it was 
thought that some of these patients had not fully appreciated the logistic demands of HBO. 
This was addressed by reinforcing informed consent.  Additionally, some trial sites 
unexpectedly withdrew funding when HBO was re-classified as a clinical trial excess 
treatment cost.  There remained a higher propensity for drop-out in the HBO versus the 
non-HBO arm even after these issues were addressed, reflecting the longer time interval 
between randomization and treatment for the HBO arm.  Despite this, demonstrable 
comparability between arms was retained, and a range of sensitivity analyses did not 
influence the primary analysis. 
 
The XXXXXX trial confirms the safety of HBO in this patient population. The toxicities related 
to pressure effects and inspired oxygen percentage were much as expected.  Previously, 
anecdotal concerns over the potential of HBO to reactivate otherwise dormant malignant 
cells have been raised for patients treated for late radiation effects. In the present trial, 
subsequent malignancies were notably common but there were no significant differences in 
incidence between the HBO and non-HBO trial arms. 
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In the light of the low incidence of ORN seen in the XXXXXX trial, amongst patients who had 
previously been considered at high risk, it is difficult to justify the future use of HBO in 
prevention of ORN associated with surgery or dental extraction in the irradiated mandible.  
These findings reverse the conclusions of the recently published Cochrane review in this 
clinical setting. Further, it would appear difficult to adequately power any subsequent ORN 
prevention trial unless a genuinely high-risk sub-set of patients could be identified, for 
example from biomarkers of susceptibility to severe late radiation effects(29,30).  The 
significance of temporary improvements in symptoms attributable to the use of HBO remain 
uncertain, and this would require alternative trial designs to further explore.  As the 
financial costs and logistic demands of HBO therapy are very high, the implications of this 
trial may include a significant economic saving for those health systems where HBO is 
currently considered a standard of care. 
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Table Legends 
 
Table 1 - Baseline characteristics of patients analyzed per protocol, i.e. completed allocated 
HBO, received surgery and followed up to 6-month primary endpoint assessment. 
 
Table 2: Acute symptoms questionnaire, by trial arm.  
These results reflect analysis of those 75% returning questionnaires (39 patients in the HBO 
arm, 36 patients in non-HBO arm). The p-values are from the joint structural equations 
model that includes Comfort at day 8; robust standard errors were used because of 
differences in variance and departures from Normality. Univariate Mann-Whitney p-values 
are also therefore displayed, in brackets. 
 
Table 3: Visual analogue pain scores at each time point 
 
 
Figure titles 
 
Figure 1: XXXXX Trial Schema 
 
Figure 2: Trial Consort diagram 
 
Figure 3: UW-QoL Composite physical scores.  
The physical subscale score is computed as an average of 6 domain scores: chewing, 
swallowing, speech, taste, saliva and appearance. A change of 12 units is deemed a large 
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change, one of 7.5 units a moderate. 0 represents the worst possible and 100 the best 
possible QoL. 
 
Figure 4: UW-Q0L Composite social-emotional scores.  
The social-emotional subscale score is computed as an average of 6 domain scores: anxiety, 
mood, pain, activity, recreation, shoulder. A change of 12 units is deemed a large change, 
one of 7.5 units a moderate. 0 represents the worst possible and 100 the best possible QoL. 
Figure 5: Clinical photograph of exposed bone: Minor Bone Spicules (MBS) – two areas of 
bone <20mm
2 (1)
 in left posterior mandible 6 months after dental extraction. Minimal bone 
exposure subject to spontaneous exfoliation and subsequent healing by 12 months. 
 
Figure 6: Clinical photograph of exposed bone: Notani grade 2 Osteoradionecrosis in right 
posterior mandible 12 months after molar tooth extraction. This area of exposed bone has 
progressed from Notani grade 1 at 6 months. 
 
 
Supplemental documents 
 
Supplemental Table 1: Classification and definition of primary outcome in XXXXX trial 
 
Supplemental Table 2:  Linear mixed modelling of pain scores. Analysis of pain scores over 
the study are further analysed using a linear mixed modelling approach including a square 
root transformation on the observed pain score.  A random intercept and slope model was 
applied, including fixed effects for treatment arm, time and the treatment by time 
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interaction.  Change in pain score [mean (se)] reduced by 0.044 (0.044) pain units per month 
in the non-HBO arm and reduced by 0.076 (0.045) units per month in the HBO arm.  
 
Supplemental Table 3: CTCAE toxicities within patients receiving HBO. 
N(%) of patients with any adverse event related to HBO for all 58 patients receiving HBO; 
includes events occurring within 6 months of most recent HBO treatment.  
Note: as recorded the SAE severity codes are 0 = Mild, 1 = Moderate, 2 = Severe; these have 
been aligned with the AE codes (the interpretation of an SAE severity of 3 or more is that 
this includes AE codes of 4 & 5 as well).  
 
Supplemental Table 4:  Summary of sensitivity analysis. Sensitivity analyses are performed 
under a range of differing assumptions for the primary outcome.  Included are Sensitivity 
analysis where ORN is developed in line with the best and worst case scenarios (A and B) as 
well as scenarios in line with risk for development.  For none of the analyses reported is 
there any notable deviation away from the reported Odds Ratio for the primary analysis [OR 
= 1.13 (0.14 – 8.92)].  Further sensitivity analyses were planned using multiple imputation to 
account for missing data but these results are not presented due to difficulties with model 
convergence.   
 
Further to this, sensitivity analyses were performed to illustrate patterns of imputed 
outcomes where data are unavailable which would result in study interpretations which 
differ from those reported.  Here, if it is assumed that the response rate is fixed at 6.4% in 
the missing data for the HBO group control arm, we would need to observe a ORN rate of 
18% in the missing data of the standard care arm to determine statistical significance.  If the 
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response rate is fixed at 3.2% in the missing data for the HBO group control arm, we would 
need to observe a ORN rate of 15% in the missing data of the standard care arm to 
determine statistical significance.   
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Characteristic (Reviewed patients) HBO arm (47) Control arm (53) TOTAL (100) 
Age yrs mean (SD) 58.3 (10) 58.2 (10.4) 58.2 (10.1) 
Males, n(%) 14 (30%) 14 (27%) 28 (28%) 
Smoking, n(%) 
 
Never 14 (29%) 17 (32%) 31 (31%) 
Past 23 (48%) 26 (49%) 49 (49%) 
Current 10 (21%) 10 (18%) 20 (20%) 
Missing 0 (0%) 0 (0%) 0 (0%) 
Alcohol n(%) 
 
Never 4 (12%) 3 (7%) 7 (10%) 
Past 5 (15%) 10 (25%) 15 (21%) 
Current 24 (72%) 26 (66%) 50 (69%) 
Missing 14 (42%) 14 (35%) 28 (28%) 
Radiotherapy  
Radiotherapy dose (Gy) mean (SD 62.8 (7.8) 63 (10.2) 62.9 (9.1) 
Radiotherapy duration (wks) mean (SD) 6.1 (1.6) 6.2 (1.7) 6.2 (1.7) 
 
Table 1- Baseline characteristics of patients analysed per protocol, i.e. completed allocated 
HBO, received surgery and followed up to 6-month primary endpoint assessment. 
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Post-
surgery 
Day 
HBO pain 
Standard 
pain 
HBO 
swelling 
Standard 
swelling 
HBO 
bleeding 
Standard 
bleeding 
HBO 
opening 
mouth 
Standard 
opening 
mouth 
HBO 
eating 
Standard 
eating 
1 
2.55 (SD 
= 1.17; N 
= 42) 
2.92 (SD = 
1.09; N = 
37) 
2.25 (SD = 
1.03; N = 
40) 
2.65 (SD = 
1.18; N = 
37) 
1.83 (SD = 
.97; N = 41) 
2.3 (SD = 
1.02; N = 
37) 
1.73 (SD = 
.99; N = 
40) 
2.58 (SD = 
1.32; N = 
36) 
2.98 (SD = 
1.42; N = 
40) 
4.03 (SD = 
1.28; N = 
32) 
2 
2.19 (SD 
= 1.06; N 
= 42) 
2.7 (SD = 
1.13; N = 
37) 
2.07 (SD = 
.96; N = 41) 
2.59 (SD = 
1.17; N = 
37) 
1.32 (SD = 
.57; N = 41) 
1.7 (SD = 
.81; N = 37) 
1.67 (SD = 
.84; N = 
39) 
2.56 (SD = 
1.23; N = 
36) 
2.5 (SD = 
1.4; N = 
40) 
3.85 (SD = 
1.3; N = 33) 
3 
2.12 (SD 
= 1.09; N 
= 42) 
2.43 (SD = 
1.07; N = 
37) 
1.83 (SD = 
.8; N = 41) 
2.38 (SD = 
.92; N = 37) 
1.12 (SD = 
.4; N = 41) 
1.44 (SD = 
.73; N = 36) 
1.48 (SD = 
.75; N = 
40) 
2.49 (SD = 
1.24; N = 
37) 
2.28 (SD = 
1.36; N = 
40) 
3.68 (SD = 
1.42; N = 
31) 
4 
1.83 (SD 
= .93; N = 
42) 
2.16 (SD = 
.99; N = 37) 
1.66 (SD = 
.76; N = 41) 
1.95 (SD = 
.97; N = 37) 
1.12 (SD = 
.4; N = 41) 
1.28 (SD = 
.61; N = 36) 
1.33 (SD = 
.62; N = 
40) 
2.16 (SD = 
1.19; N = 
37) 
2.13 (SD = 
1.42; N = 
40) 
3.36 (SD = 
1.37; N = 
33) 
5 
1.78 (SD 
= 1.08; N 
= 41) 
2.16 (SD = 
1.04; N = 
37) 
1.43 (SD = 
.64; N = 40) 
1.73 (SD = 
.77; N = 37) 
1.13 (SD = 
.33; N = 40) 
1.3 (SD = 
.62; N = 37) 
1.31 (SD = 
.47; N = 
39) 
2.08 (SD = 
1.19; N = 
37) 
2.08 (SD = 
1.35; N = 
39) 
3.18 (SD = 
1.53; N = 
33) 
6 
1.68 (SD 
= 1.01; N 
= 41) 
1.92 (SD = 
1.06; N = 
37) 
1.41 (SD = 
.64; N = 39) 
1.61 (SD = 
.73; N = 36) 
1.05 (SD = 
.22; N = 40) 
1.16 (SD = 
.44; N = 37) 
1.28 (SD = 
.46; N = 
39) 
2 (SD = 1.2; 
N = 37) 
2 (SD = 
1.3; N = 
39) 
3.06 (SD = 
1.62; N = 
33) 
7 
1.59 (SD 
= .92; N = 
41) 
1.97 (SD = 
1.07; N = 
37) 
1.31 (SD = 
.47; N = 39) 
1.51 (SD = 
.69; N = 37) 
1.02 (SD = 
.16; N = 40) 
1.31 (SD = 
.86; N = 36) 
1.26 (SD = 
.5; N = 39) 
1.97 (SD = 
1.13; N = 
36) 
1.9 (SD = 
1.29; N = 
39) 
2.82 (SD = 
1.57; N = 
33) 
Mean 
AUC 
11.53 (SD 
= 5.55; N 
= 42) 
13.79 (SD = 
5.69; N = 
37) 
9.97 (SD = 
3.79; N = 
41) 
12.36 (SD = 
4.74; N = 
37) 
7.03 (SD = 
1.79; N = 
41) 
8.54 (SD = 
3.28; N = 
37) 
8.44 (SD = 
3.51; N = 
40) 
13.43 (SD = 
6.79; N = 
37) 
13.18 (SD 
= 7.49; N 
= 40) 
20.42 (SD = 
8.14; N = 
33) 
P-value 
 
.1625 
(.0458) 
 
.0207 
(.0182) 
 
.0167 
(.0375) 
 
.0007 
(.0004) 
 
.0002 
(.0004) 
 
Table 2:  
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Acute symptoms questionnaire, by trial arm.  
These results reflect analysis of those 75% returning questionnaires (39 patients in the HBO arm, 36 patients in non-HBO arm). The p-values 
are from the joint structural equations model that includes Comfort at day 8; robust standard errors were used because of differences in 
variance and departures from Normality. Univariate Mann-Whitney p-values are also therefore displayed, in brackets. 
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Assessment HBO Non-HBO 
Difference (HBO minus Standard) 
in fitted means 
Baseline 
.164 (SD =.213)  
Median =.063  
IQR =  .011 to .234  
N = 67 
.232 (SD =.289)  
Median = .074  
IQR =  .02 to .389  
N = 69 
-.075 (95% CI: -.15 to -.001)  
P = .046 
3 months 
.115 (SD =.199)  
Median =.02  
IQR =  0 to .168  
N = 46 
.18 (SD =.232)  
Median = .04  
IQR =  .011 to .38  
N = 55 
-.057 (95% CI: -.115 to 0)  
P = .049 
6 months 
.116 (SD =.206)  
Median =.02  
IQR =  0 to .106  
N = 51 
.153 (SD =.232)  
Median = .03  
IQR =  .011 to .21  
N = 54 
-.06 (95% CI: -.121 to 0)  
P = .049 
12 months 
.111 (SD =.179)  
Median =.021  
IQR =  0 to .168  
N = 44 
.252 (SD =.299)  
Median = .101  
IQR =  .011 to .441  
N = 48 
-.076 (95% CI: -.151 to -.001)  
P = .048 
 
Table 3 : Visual analogue pain scores at each time point 
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Experimental Treatment Arm:
10 daily HBO dives
Chlorohexidine mouthwash
Antibiotics
Surgery
Acute Symptoms Questionnaire x 7 days
High risk patients:
Require surgery to mandible with >50Gy radiotherapy
4 week run in: Eligibility, patient information, consent
1:1 Randomisation
Acute Symptoms Questionnaire x 7 days
Late follow up (at closure of trial) 
Implant loss
* Radiograph at 3/12 
and 12/12 only if ORN 
present
Standard Management Arm:
Chlorohexidine mouthwash
Antibiotics
Surgery
12 month follow up
Healing, QOL, pain, photograph*, radiograph
6 month follow up
Healing, QOL, pain, photograph, radiograph
3 month follow up
Healing, QOL, pain, photograph*, radiograph
Enrollment
Allocation
Follow-up
Analysis
20 daily HBO dives
Baseline assessment:
QOL, pain, photograph, radiograph
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Figure 2: Consort diagram  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.1 Assessment of data quality 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n= 256 ) 
Excluded  (n= 129 ) 
♦   Clinical decision/Not meeting 
inclusion criteria (n= 43 ) 
♦   Patient choice (n= 59 ) 
♦  Other reasons (n= 5 ) 
♦  No reason specified (n= 22 ) 
 
♦ Ineligible on review (n=1) 
♦ Analysed for primary EP (n= 47) blind review 
 
 
♦Discontinued intervention  
• Withdrew after surgery (n = 6)  
• Lost to follow-up after surgery (n= 1) 
Patients Available for final analysis (n=48) 
 
Discontinued intervention following final analysis 
• Withdrew from study (n = 4)  
Allocated to HBO (n= 72 ) 
♦ Did not receive allocated intervention  
• Withdrew before HBO (n=14 ) 
• Withdrew during/after HBO before surgery (n= 3 ) 
Received HBO+Surgery (n= 55 ) 
Discontinued intervention prior to final analysis 
• Withdrew after surgery (n = 10)  
• Lost to follow-up after surgery (n= 2) 
Patients Available for final analysis (n=54) 
 
Discontinued intervention following final analysis 
• Withdrew from study (n = 3)  
Allocated to Standard care (n=72  ) 
♦ Did not receive allocated intervention  
• Withdrew before surgery (n= 6 ) 
Received Surgery (n=66) 
♦ Ineligible on review (n=1) 
Analysed for primary EP (n= 53) blind review 
Allocation 
Analysis 
Follow-Up 
Randomized (n=144  ) 
Enrollment 
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Summary: 
 
The results of this multicentre randomized controlled trial refute earlier positive results for 
hyperbaric oxygen therapy in the prevention of mandibular osteoradionecrosis. Both arms 
had a very low rate, overall 6%, of osteoradionecrosis. This is only the second randomized 
trial carried out in this setting, and the only one in the era of modern radiotherapy 
techniques. Our results suggest the continued widespread prescription of HBO in prevention 
of mandibular osteoradionecrosis is not justified. 
 
